연구동향 분석

Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults

Nam Su Youn Jeon Seong Woo Jung Deuk Kju Heo Sung-Jae 2022년

논문상세정보
인용/피인용
' Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • Anti-SARS-CoV-2 antibodies
  • COVID-19
  • Vaccination
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
5,682 0

0.0%

' Body Weight is Inversely Associated with Anti-SARS-CoV-2 Antibody Levels after BNT162b2 mRNA Vaccination in Young and Middle Aged Adults' 의 참고문헌

  • mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern
    Goel RR [2021]
  • The how’s and what’s of vaccine reactogenicity
    Hervé C [2019]
  • The association between obesity and peak antibody titer response in COVID-19 infection
    Soffer S [2021]
  • Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
    Lan , J. [2020]
  • Simplified calculation of body-surface area
  • Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine
    Yamamoto S [2022]
  • Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates
    Walsh EE [2020]
  • Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 : a preliminary report of a phase 1/2, single-blind, randomised controlled trial
  • Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002) : a single-blind, randomised, controlled, phase 2/3 trial
    Ramasamy MN [2021]
  • Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
    Polack FP [2020]
  • SARS-CoV-2 vaccines in development
    Krammer F [2020]
  • Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
  • Phase 1-2trial of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine
    Keech C [2020]
  • Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
    Khoury DS [2021]
  • Low antispike antibody levels correlate with poor outcomes in COVID-19 breakthrough hospitalizations
    Sanghavi DK [2022]
  • Healthcare Workforce Response to The Coronavirus Disease Outbreak in Daegu, Korea: A Multi-Center, Cross-Sectional Survey
  • Demographic and clinical factors associated with anti-SARS-CoV-2 antibody levels after 2 BNT162b2 mRNA vaccine doses
    Nam SY [2022]
  • Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals
  • Can reactogenicity predict immunogenicity after COVID-19 vaccination?
  • Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England : a population-based cohort study
    Piernas C [2022]
  • An mRNA vaccine against SARS-CoV-2- preliminary report
    Jackson, LA [2020]